Recognized for decades as a harbinger of glomerular injury, albuminuria has long been accepted as the earliest marker of kidney disease. With compelling evidence linking albuminuria to chronic kidney disease (CKD) progression, cardiovascular risk, and death, it has served as the treatment target for nephrologists and clinical trial endpoint of CKD-focused pharmaceutical development.1,2 Despite the strong association between albuminuria and poor outcomes for patients with CKD, population-wide screening efforts have long been stalled by arguments that few treatment options existed for those who screened positive.